HIV molecular immunology database

 

Search the Epitope Variant and Escape Mutation Database

Help


Found 6 matching records:

Displaying record number 57432

HXB2 Location  Gag(216-224)   Gag Epitope Map
View variants at this location
Epitope HPVHAGPVA   Epitope Alignment
Variants
HPVqAGPVA   non-susceptible form; susceptible form
HPVHAGPiA   non-susceptible form; susceptible form
HPVHAGPip   non-susceptible form; susceptible form
HPVHAGPVp   non-susceptible form; susceptible form
HPaHAGPVA   non-susceptible form; susceptible form
HPVaAGPVA   non-susceptible form; susceptible form
HPVHvGPVA   non-susceptible form; susceptible form
HPVHAaPVA   non-susceptible form; susceptible form
Epitope Name HA9
Species (MHC/HLA human(B7 supertype)

Variant Details

Showing all: 8 variant(s).


Variant ID.  2472
Epitope Seq.  HPVHAGPVA
Variant Seq.  HPVqAGPVA
Mutations H/Q
Epitope Location H4Q
HXB2 Location H219Q
Mutation Type NSF: non-susceptible form
SF: susceptible form
Epitope Subtype A1, C, D
Variant Subtype C, D
Method CD8 T-cell Elispot - IFNy
Note Patients 2295 (Caucasian female, experienced some treatment, autologous virus Clade C) and 2840 (African female, treated, autologous virus Clade D) continued to elicit response to variant HPVqAGPVA, but cells encountering this variant were not susceptible in patient 2632 (African female, experienced some treatment, autologous virus Clade A1).


Variant ID.  2473
Epitope Seq.  HPVHAGPVA
Variant Seq.  HPVHAGPiA
Mutations V/I
Epitope Location V8I
HXB2 Location V223I
Mutation Type NSF: non-susceptible form
SF: susceptible form
Epitope Subtype A1, C, D
Variant Subtype C, D
Method CD8 T-cell Elispot - IFNy
Note Patients 2295 (Caucasian female, experienced some treatment, autologous virus Clade C) and 2840 (African female, treated, autologous virus Clade D) continued to elicit response to variant HPVHAGPiA, but cells encountering this variant were not susceptible in patient 2632 (African female, experienced some treatment, autologous virus Clade A1).


Variant ID.  2474
Epitope Seq.  HPVHAGPVA
Variant Seq.  HPVHAGPip
Mutations V/I A/P
Epitope Location V8I A9P
HXB2 Location V223I A224P
Mutation Type NSF: non-susceptible form
SF: susceptible form
Epitope Subtype A1, C, D
Variant Subtype C, D
Method CD8 T-cell Elispot - IFNy
Note Patients 2295 (Caucasian female, experienced some treatment, autologous virus Clade C) and 2840 (African female, treated, autologous virus Clade D) continued to elicit response to variant HPVHAGPip, but cells encountering this variant were not susceptible in patient 2632 (African female, experienced some treatment, autologous virus Clade A1).


Variant ID.  2475
Epitope Seq.  HPVHAGPVA
Variant Seq.  HPVHAGPVp
Mutations A/P
Epitope Location A9P
HXB2 Location A224P
Mutation Type NSF: non-susceptible form
SF: susceptible form
Epitope Subtype A1, C, D
Variant Subtype C, D
Method CD8 T-cell Elispot - IFNy
Note Patients 2295 (Caucasian female, experienced some treatment, autologous virus Clade C) and 2840 (African female, treated, autologous virus Clade D) continued to elicit response to variant HPVHAGPVp, but cells encountering this variant were not susceptible in patient 2632 (African female, experienced some treatment, autologous virus Clade A1).


Variant ID.  2476
Epitope Seq.  HPVHAGPVA
Variant Seq.  HPaHAGPVA
Mutations V/A
Epitope Location V3A
HXB2 Location V218A
Mutation Type NSF: non-susceptible form
SF: susceptible form
Epitope Subtype A1, C, D
Variant Subtype C, D
Method CD8 T-cell Elispot - IFNy
Note Patients 2295 (Caucasian female, experienced some treatment, autologous virus Clade C) and 2840 (African female, treated, autologous virus Clade D) continued to elicit response to variant HPaHAGPVA, but cells encountering this variant were not susceptible in patient 2632 (African female, experienced some treatment, autologous virus Clade A1).


Variant ID.  2477
Epitope Seq.  HPVHAGPVA
Variant Seq.  HPVaAGPVA
Mutations H/A
Epitope Location H4A
HXB2 Location H219A
Mutation Type NSF: non-susceptible form
SF: susceptible form
Epitope Subtype A1, C, D
Variant Subtype D
Method CD8 T-cell Elispot - IFNy
Note Patient 2840 (African female, treated, autologous virus Clade D) continued to elicit response to variant HPVaAGPVA, but cells encountering this variant were not susceptible in patients 2632 (African female, experienced some treatment, autologous virus Clade A1) and 2295 (Caucasian female, experienced some treatment, autologous virus Clade C).


Variant ID.  2478
Epitope Seq.  HPVHAGPVA
Variant Seq.  HPVHvGPVA
Mutations A/V
Epitope Location A5V
HXB2 Location A220V
Mutation Type NSF: non-susceptible form
SF: susceptible form
Epitope Subtype A1, C, D
Variant Subtype C, D
Method CD8 T-cell Elispot - IFNy
Note Patients 2295 (Caucasian female, experienced some treatment, autologous virus Clade C) and 2840 (African female, treated, autologous virus Clade D) continued to elicit response to variant HPVHvGPVA, but cells encountering this variant were not susceptible in patient 2632 (African female, experienced some treatment, autologous virus Clade A1).


Variant ID.  2479
Epitope Seq.  HPVHAGPVA
Variant Seq.  HPVHAaPVA
Mutations G/A
Epitope Location G6A
HXB2 Location G221A
Mutation Type NSF: non-susceptible form
SF: susceptible form
Epitope Subtype A1, C, D
Variant Subtype C, D
Method CD8 T-cell Elispot - IFNy
Note Patients 2295 (Caucasian female, experienced some treatment, autologous virus Clade C) and 2840 (African female, treated, autologous virus Clade D) continued to elicit response to variant HPVHAaPVA, but cells encountering this variant were not susceptible in patient 2632 (African female, experienced some treatment, autologous virus Clade A1).

References

Hoof2010 Ilka Hoof, Carina L. Pérez, Marcus Buggert, Rasmus K. L. Gustafsson, Morten Nielsen, Ole Lund, and Annika C. Karlsson. Interdisciplinary Analysis of HIV-Specific CD8+ T Cell Responses against Variant Epitopes Reveals Restricted TCR Promiscuity. J Immunol, 184(9):5383-5391, 1 May 2010. PubMed ID: 20363973. Show all entries for this paper.


Displaying record number 57493

HXB2 Location  Gag(259-267)   Gag Epitope Map
View variants at this location
Epitope GEIYKRWII   Epitope Alignment
Variants
GdIYKRWII   susceptible form
GEIYKRWIv   susceptible form
GEIYKaWII   non-susceptible form; susceptible form
GEIYaRWII   non-susceptible form
GEIaKRWII   non-susceptible form; susceptible form
GEIYrRWII   susceptible form
Epitope Name GI9
Species (MHC/HLA human

Variant Details

Showing all: 6 variant(s).


Variant ID.  2480
Epitope Seq.  GEIYKRWII
Variant Seq.  GdIYKRWII
Mutations E/D
Epitope Location E2D
HXB2 Location E260D
Mutation Type SF: susceptible form
Epitope Subtype B
Variant Subtype B
Method CD8 T-cell Elispot - IFNy
Note Patients 2275 (Latin male, experienced some treatment, autologous virus Clade B); 2792 (Caucasian female, treatment naive, autologous virus Clade B); 2902 (Caucasian male, treated, autologous virus Clade B) all continued to elicit CTL response to variant GdIYKRWII.


Variant ID.  2481
Epitope Seq.  GEIYKRWII
Variant Seq.  GEIYKRWIv
Mutations I/V
Epitope Location I9V
HXB2 Location I267V
Mutation Type SF: susceptible form
Epitope Subtype B
Variant Subtype B
Method CD8 T-cell Elispot - IFNy
Note Patients 2275 (Latin male, experienced some treatment, autologous virus Clade B); 2792 (Caucasian female, treatment naive, autologous virus Clade B); 2902 (Caucasian male, treated, autologous virus Clade B) all continued to elicit CTL response to variant GEIYKRWIv.


Variant ID.  2482
Epitope Seq.  GEIYKRWII
Variant Seq.  GEIYKaWII
Mutations R/A
Epitope Location R6A
HXB2 Location R264A
Mutation Type NSF: non-susceptible form
SF: susceptible form
Epitope Subtype B
Variant Subtype B
Method CD8 T-cell Elispot - IFNy
Note Patients 2275 (Latin male, experienced some treatment, autologous virus Clade B); 2792 (Caucasian female, treatment naive, autologous virus Clade B) both continued to elicit CTL response to variant GEIYKaWII, but patient 2902 (Caucasian male, treated, autologous virus Clade B) did not elicit a response upon encountering this variant.


Variant ID.  2483
Epitope Seq.  GEIYKRWII
Variant Seq.  GEIYaRWII
Mutations K/A
Epitope Location K5A
HXB2 Location K263A
Mutation Type NSF: non-susceptible form
Epitope Subtype B
Variant Subtype B
Method CD8 T-cell Elispot - IFNy
Note All 3 patients, 2275 (Latin male, experienced some treatment, autologous virus Clade B); 2792 (Caucasian female, treatment naive, autologous virus Clade B); 2902 (Caucasian male, treated, autologous virus Clade B) did not elicit CTL responses to variant GEIYaRWII.


Variant ID.  2484
Epitope Seq.  GEIYKRWII
Variant Seq.  GEIaKRWII
Mutations Y/A
Epitope Location Y4A
HXB2 Location Y262A
Mutation Type NSF: non-susceptible form
SF: susceptible form
Epitope Subtype B
Variant Subtype B
Method CD8 T-cell Elispot - IFNy
Note Patient 2792 (Caucasian female, treatment naive, autologous virus Clade B) both continued to elicit CTL response to variant GEIaKRWII, but patients 2902 (Caucasian male, treated, autologous virus Clade B) and 2275 (Latin male, experienced some treatment, autologous virus Clade B)did not elicit a response upon encountering this variant.


Variant ID.  2485
Epitope Seq.  GEIYKRWII
Variant Seq.  GEIYrRWII
Mutations K/R
Epitope Location K5R
HXB2 Location K263R
Mutation Type SF: susceptible form
Epitope Subtype B
Variant Subtype B
Method CD8 T-cell Elispot - IFNy
Note Patients 2275 (Latin male, experienced some treatment, autologous virus Clade B); 2792 (Caucasian female, treatment naive, autologous virus Clade B); 2902 (Caucasian male, treated, autologous virus Clade B) all continued to elicit CTL response to variant GEIYrRWII.

References

Hoof2010 Ilka Hoof, Carina L. Pérez, Marcus Buggert, Rasmus K. L. Gustafsson, Morten Nielsen, Ole Lund, and Annika C. Karlsson. Interdisciplinary Analysis of HIV-Specific CD8+ T Cell Responses against Variant Epitopes Reveals Restricted TCR Promiscuity. J Immunol, 184(9):5383-5391, 1 May 2010. PubMed ID: 20363973. Show all entries for this paper.


Displaying record number 57497

HXB2 Location  Pol(311-319)   Pol Epitope Map
View variants at this location
Epitope SPAIFQSSM   Epitope Alignment
Variants
SPsIFQSSM   susceptible form
SPAIFQcSM   susceptible form
SPAIFQaSM   susceptible form
SPsIFQcSM   non-susceptible form; susceptible form
SPAIFaSSM   non-susceptible form; susceptible form
SPAaFQSSM   non-susceptible form
SPAIaQSSM   non-susceptible form
Epitope Name SM9
Species (MHC/HLA human

Variant Details

Showing all: 7 variant(s).


Variant ID.  2497
Epitope Seq.  SPAIFQSSM
Variant Seq.  SPsIFQSSM
Mutations A/S
Epitope Location A3S
HXB2 Location A313S
Mutation Type SF: susceptible form
Epitope Subtype A1, B
Variant Subtype A1
Method CD8 T-cell Elispot - IFNy
Note SM9 variant, SPsIFQSSM, continued to elicit a response in patients 2632 (African female, experienced some treatment, autologous virus Clade A1) and 3076 (African female, treatment naive, autologous virus Clade A1).


Variant ID.  2498
Epitope Seq.  SPAIFQSSM
Variant Seq.  SPAIFQcSM
Mutations S/C
Epitope Location S7C
HXB2 Location S317C
Mutation Type SF: susceptible form
Epitope Subtype A1, B
Variant Subtype A1, B
Method CD8 T-cell Elispot - IFNy
Note SM9 variant SPAIFQcSM continued to elicit CTL response from all 3 patients, 2059 (Caucasian male, treated, autologous virus Clade B); 2632 (African female, experienced some treatment, autologous virus Clade A1) and 3076 (African female, treatment naive, autologous virus Clade A1).


Variant ID.  2499
Epitope Seq.  SPAIFQSSM
Variant Seq.  SPAIFQaSM
Mutations S/A
Epitope Location S7A
HXB2 Location S317A
Mutation Type SF: susceptible form
Epitope Subtype A1, B
Variant Subtype A1, B
Method CD8 T-cell Elispot - IFNy
Note SM9 variant SPAIFQaSM continued to elicit CTL response from all 3 patients, 2059 (Caucasian male, treated, autologous virus Clade B); 2632 (African female, experienced some treatment, autologous virus Clade A1) and 3076 (African female, treatment naive, autologous virus Clade A1).


Variant ID.  2500
Epitope Seq.  SPAIFQSSM
Variant Seq.  SPsIFQcSM
Mutations A/S S/C
Epitope Location A3S S7C
HXB2 Location A313S S317C
Mutation Type NSF: non-susceptible form
SF: susceptible form
Epitope Subtype A1, B
Variant Subtype A1, B
Method CD8 T-cell Elispot - IFNy
Note SM9 variant SPsIFQcSM continued to elicit CTL response in patients 2059 (Caucasian male, treated, autologous virus Clade B) and 3076 (African female, treatment naive, autologous virus Clade A1). No CTL response was seen in patient 2632 (African female, experienced some treatment, autologous virus Clade A1).


Variant ID.  2501
Epitope Seq.  SPAIFQSSM
Variant Seq.  SPAIFaSSM
Mutations Q/A
Epitope Location Q6A
HXB2 Location Q316A
Mutation Type NSF: non-susceptible form
SF: susceptible form
Epitope Subtype A1, B
Variant Subtype A1
Method CD8 T-cell Elispot - IFNy
Note SM9 variant SPAIFaSSM continued to elicit CTL response though at a low level, in patient 2632 (African female, experienced some treatment, autologous virus Clade A1). CTL from patients 2059 (Caucasian male, treated, autologous virus Clade B) and 3076 (African female, treatment naive, autologous virus Clade A1) did not respond to this variant.


Variant ID.  2502
Epitope Seq.  SPAIFQSSM
Variant Seq.  SPAaFQSSM
Mutations I/A
Epitope Location I4A
HXB2 Location I314A
Mutation Type NSF: non-susceptible form
Epitope Subtype A1, B
Method CD8 T-cell Elispot - IFNy
Note SM9 variant, SPAaFQSSM did not elicit a response in any patients - 2632 (African female, experienced some treatment, autologous virus Clade A1) and 3076 (African female, treatment naive, autologous virus Clade A1).


Variant ID.  2503
Epitope Seq.  SPAIFQSSM
Variant Seq.  SPAIaQSSM
Mutations F/A
Epitope Location F5A
HXB2 Location F315A
Mutation Type NSF: non-susceptible form
Epitope Subtype A1, B
Method CD8 T-cell Elispot - IFNy
Note SM9 variant, SPAIaQSSM did not elicit a response in any patients - 2059 (Caucasian male, treated, autologous virus Clade B); 2632 (African female, experienced some treatment, autologous virus Clade A1) and 3076 (African female, treatment naive, autologous virus Clade A1).

References

Hoof2010 Ilka Hoof, Carina L. Pérez, Marcus Buggert, Rasmus K. L. Gustafsson, Morten Nielsen, Ole Lund, and Annika C. Karlsson. Interdisciplinary Analysis of HIV-Specific CD8+ T Cell Responses against Variant Epitopes Reveals Restricted TCR Promiscuity. J Immunol, 184(9):5383-5391, 1 May 2010. PubMed ID: 20363973. Show all entries for this paper.


Displaying record number 57494

HXB2 Location  Nef(73-81)   Nef Epitope Map
View variants at this location
Epitope QVPLRPMTY   Epitope Alignment
Variants
QVPvRPMTY   susceptible form
QaPLRPMTY   non-susceptible form; susceptible form
QVPLRPMTf   non-susceptible form; susceptible form
QVPaRPMTY   non-susceptible form; susceptible form
QVPLRaMTY   non-susceptible form; susceptible form
QVPLaPMTY   non-susceptible form; susceptible form
Epitope Name QY9
Species (MHC/HLA human

Variant Details

Showing all: 6 variant(s).


Variant ID.  2486
Epitope Seq.  QVPLRPMTY
Variant Seq.  QVPvRPMTY
Mutations L/V
Epitope Location L4V
HXB2 Location L76V
Mutation Type SF: susceptible form
Epitope Subtype B, C, D
Variant Subtype C, D
Method CD8 T-cell Elispot - IFNy
Note Patients 2295 (Caucasian female, experienced some treatment, autologous virus Clade C); 2792 (Caucasian male, treatment naive, autologous virus Clade B); 2840 (African female, treated, autologous virus Clade D) all continued to elicit CTL response to variant QVPvRPMTY.


Variant ID.  2487
Epitope Seq.  QVPLRPMTY
Variant Seq.  QaPLRPMTY
Mutations V/A
Epitope Location V2A
HXB2 Location V74A
Mutation Type NSF: non-susceptible form
SF: susceptible form
Epitope Subtype B, C, D
Variant Subtype C, D
Method CD8 T-cell Elispot - IFNy
Note Patients 2295 (Caucasian female, experienced some treatment, autologous virus Clade C); 2840 (African female, treated, autologous virus Clade D) all continued to elicit CTL response to variant QaPLRPMTY, but CTL from patient 2792 (Caucasian male, treatment naive, autologous virus Clade B) were not susceptible to this variant.


Variant ID.  2488
Epitope Seq.  QVPLRPMTY
Variant Seq.  QVPLRPMTf
Mutations Y/F
Epitope Location Y9F
HXB2 Location Y81F
Mutation Type NSF: non-susceptible form
SF: susceptible form
Epitope Subtype B, C, D
Variant Subtype C, D
Method CD8 T-cell Elispot - IFNy
Note Patients 2295 (Caucasian female, experienced some treatment, autologous virus Clade C); 2840 (African female, treated, autologous virus Clade D) all continued to elicit CTL response to variant QVPLRPMTf, but CTL from patient 2792 (Caucasian male, treatment naive, autologous virus Clade B) were not susceptible to this variant.


Variant ID.  2489
Epitope Seq.  QVPLRPMTY
Variant Seq.  QVPaRPMTY
Mutations L/A
Epitope Location L4A
HXB2 Location L76A
Mutation Type NSF: non-susceptible form
SF: susceptible form
Epitope Subtype B, C, D
Variant Subtype D
Method CD8 T-cell Elispot - IFNy
Note Patient 2840 (African female, treated, autologous virus Clade D) continued to elicit CTL response to variant QVPaRPMTY, but CTL from patients 2295 (Caucasian female, experienced some treatment, autologous virus Clade C); 2792 (Caucasian male, treatment naive, autologous virus Clade B) were not susceptible to this variant.


Variant ID.  2491
Epitope Seq.  QVPLRPMTY
Variant Seq.  QVPLRaMTY
Mutations P/A
Epitope Location P6A
HXB2 Location P78A
Mutation Type NSF: non-susceptible form
SF: susceptible form
Epitope Subtype B, C, D
Variant Subtype D
Method CD8 T-cell Elispot - IFNy
Note Patient 2840 (African female, treated, autologous virus Clade D) continued to elicit CTL response to variant QVPLRaMTY, but CTL from patients 2295 (Caucasian female, experienced some treatment, autologous virus Clade C); 2792 (Caucasian male, treatment naive, autologous virus Clade B) were not susceptible to this variant.


Variant ID.  2492
Epitope Seq.  QVPLRPMTY
Variant Seq.  QVPLaPMTY
Mutations R/A
Epitope Location R5A
HXB2 Location R77A
Mutation Type NSF: non-susceptible form
SF: susceptible form
Epitope Subtype B, C, D
Variant Subtype C
Method CD8 T-cell Elispot - IFNy
Note Patient 2295 (Caucasian female, experienced some treatment, autologous virus Clade C) continued to elicit CTL response to variant QVPLaPMTY, but CTL from patients 2840 (African female, treated, autologous virus Clade D); 2792 (Caucasian male, treatment naive, autologous virus Clade B) were not susceptible to this variant.

References

Hoof2010 Ilka Hoof, Carina L. Pérez, Marcus Buggert, Rasmus K. L. Gustafsson, Morten Nielsen, Ole Lund, and Annika C. Karlsson. Interdisciplinary Analysis of HIV-Specific CD8+ T Cell Responses against Variant Epitopes Reveals Restricted TCR Promiscuity. J Immunol, 184(9):5383-5391, 1 May 2010. PubMed ID: 20363973. Show all entries for this paper.


Displaying record number 57495

HXB2 Location  Nef(84-92)   Nef Epitope Map
View variants at this location
Epitope AVDLSHFLK   Epitope Alignment
Variants
AlDLSHFLK   non-susceptible form; susceptible form
AVDLgHFLK   non-susceptible form; susceptible form
AVDLaHFLK   non-susceptible form; susceptible form
AVDLSfFLK   non-susceptible form
AVDLSaFLK   non-susceptible form
AVDaSHFLK   non-susceptible form; susceptible form
AfDLSfFLK   non-susceptible form; susceptible form
Epitope Name AK9
Species (MHC/HLA human

Variant Details

Showing all: 7 variant(s).


Variant ID.  2504
Epitope Seq.  AVDLSHFLK
Variant Seq.  AlDLSHFLK
Mutations V/L
Epitope Location V2L
HXB2 Location V85L
Mutation Type NSF: non-susceptible form
SF: susceptible form
Epitope Subtype A1, B, D
Variant Subtype A1, B, D
Method CD8 T-cell Elispot - IFNy
Note AK9 variant, AlDLSHFLK, was the autologous form for patients 2632 and 2840 who had a CTL response to this peptide. Patient 2275 did not have a CTL response to this variant.


Variant ID.  2505
Epitope Seq.  AVDLSHFLK
Variant Seq.  AVDLgHFLK
Mutations S/G
Epitope Location S5G
HXB2 Location S88G
Mutation Type NSF: non-susceptible form
SF: susceptible form
Epitope Subtype A1, B, D
Variant Subtype A1, D
Method CD8 T-cell Elispot - IFNy
Note AK9 variant, AVDLgHFLK elicited CTL response in patients 2632 and 2840. Patient 2275 did not have a CTL response to this variant.


Variant ID.  2506
Epitope Seq.  AVDLSHFLK
Variant Seq.  AVDLaHFLK
Mutations S/A
Epitope Location S5A
HXB2 Location S88A
Mutation Type NSF: non-susceptible form
SF: susceptible form
Epitope Subtype A1, B, D
Variant Subtype A1, D
Method CD8 T-cell Elispot - IFNy
Note AK9 variant, AVDLaHFLK, elicited CTL response in patients 2632 and 2840. Patient 2275 did not have a CTL response to this variant.


Variant ID.  2508
Epitope Seq.  AVDLSHFLK
Variant Seq.  AVDLSfFLK
Mutations H/F
Epitope Location H6F
HXB2 Location H89F
Mutation Type NSF: non-susceptible form
Epitope Subtype A1, B, D
Method CD8 T-cell Elispot - IFNy
Note AK9 variant, AVDLSfFLK, was not able to elicit CTL response in any of the patients tested - 2632, 2840 and 2275.


Variant ID.  2510
Epitope Seq.  AVDLSHFLK
Variant Seq.  AVDLSaFLK
Mutations H/A
Epitope Location H6A
HXB2 Location H89A
Mutation Type NSF: non-susceptible form
Epitope Subtype A1, B, D
Method CD8 T-cell Elispot - IFNy
Note AK9 variant, AVDLSaFLK, was not able to elicit CTL response in any of the patients tested - 2632, 2840 and 2275.


Variant ID.  2511
Epitope Seq.  AVDLSHFLK
Variant Seq.  AVDaSHFLK
Mutations V/L
Epitope Location V2L
HXB2 Location V85L
Mutation Type NSF: non-susceptible form
SF: susceptible form
Epitope Subtype A1, B, D
Variant Subtype D
Method CD8 T-cell Elispot - IFNy
Note AK9 variant, AVDaSHFLK, elicited a CTL response to this peptide in patient 2840 only. Patients 2632 and 2275 did not have a CTL response to this variant.


Variant ID.  2512
Epitope Seq.  AVDLSHFLK
Variant Seq.  AfDLSfFLK
Mutations V/F H/F
Epitope Location V2F H6F
HXB2 Location V85F H89F
Mutation Type NSF: non-susceptible form
SF: susceptible form
Epitope Subtype A1, B, D
Variant Subtype D
Method CD8 T-cell Elispot - IFNy
Note AK9 variant, AfDLSfFLK, was the autologous form in patient 2275 in whom it was able to elicit CTL response. Patients 2632 and 2840 did not show any response to this variant.

References

Hoof2010 Ilka Hoof, Carina L. Pérez, Marcus Buggert, Rasmus K. L. Gustafsson, Morten Nielsen, Ole Lund, and Annika C. Karlsson. Interdisciplinary Analysis of HIV-Specific CD8+ T Cell Responses against Variant Epitopes Reveals Restricted TCR Promiscuity. J Immunol, 184(9):5383-5391, 1 May 2010. PubMed ID: 20363973. Show all entries for this paper.


Displaying record number 57496

HXB2 Location  Nef(107-115)   Nef Epitope Map
View variants at this location
Epitope QEILDLWVY   Epitope Alignment
Variants
QdILDLWVY   susceptible form
QEILDLWiY   susceptible form
QEILDaWVY   susceptible form
QEIaDLWVY   susceptible form
QEILDLWVh   non-susceptible form
QEILaLWVY   non-susceptible form
Epitope Name QY9
Species (MHC/HLA human

Variant Details

Showing all: 6 variant(s).


Variant ID.  2493
Epitope Seq.  QEILDLWVY
Variant Seq.  QdILDLWVY
Mutations E/D
Epitope Location E2D
HXB2 Location E108D
Mutation Type SF: susceptible form
Epitope Subtype B
Variant Subtype B
Method CD8 T-cell Elispot - IFNy
Note Variant QdILDLWVY continued to elicit CTL response in patient 2255 (Caucasian female, treated, autologous virus Clade B).


Variant ID.  2494
Epitope Seq.  QEILDLWVY
Variant Seq.  QEILDLWiY
Mutations V/I
Epitope Location V8I
HXB2 Location V114I
Mutation Type SF: susceptible form
Epitope Subtype B
Variant Subtype B
Method CD8 T-cell Elispot - IFNy
Note Variant QEILDLWiY continued to elicit CTL response in patient 2255 (Caucasian female, treated, autologous virus Clade B).


Variant ID.  2495
Epitope Seq.  QEILDLWVY
Variant Seq.  QEILDaWVY
Mutations L/A
Epitope Location L6A
HXB2 Location L112A
Mutation Type SF: susceptible form
Epitope Subtype B
Variant Subtype B
Method CD8 T-cell Elispot - IFNy
Note Variant QEILDaWVY continued to elicit CTL response in patient 2255 (Caucasian female, treated, autologous virus Clade B).


Variant ID.  2496
Epitope Seq.  QEILDLWVY
Variant Seq.  QEIaDLWVY
Mutations L/A
Epitope Location L4A
HXB2 Location L110A
Mutation Type SF: susceptible form
Epitope Subtype B
Variant Subtype B
Method CD8 T-cell Elispot - IFNy
Note Variant QEIaDLWVY continued to elicit CTL response though at a low level in patient 2255 (Caucasian female, treated, autologous virus Clade B).


Variant ID.  2513
Epitope Seq.  QEILDLWVY
Variant Seq.  QEILDLWVh
Mutations Y/H
Epitope Location Y9H
HXB2 Location Y115H
Mutation Type NSF: non-susceptible form
Epitope Subtype B
Variant Subtype B
Method CD8 T-cell Elispot - IFNy
Note Variant QEILDLWVh did not elicit CTL response in patient 2255 (Caucasian female, treated, autologous virus Clade B).


Variant ID.  2514
Epitope Seq.  QEILDLWVY
Variant Seq.  QEILaLWVY
Mutations D/A
Epitope Location D5A
HXB2 Location D111A
Mutation Type NSF: non-susceptible form
Epitope Subtype B
Variant Subtype B
Method CD8 T-cell Elispot - IFNy
Note Variant QEILaLWVY did not elicit CTL response in patient 2255 (Caucasian female, treated, autologous virus Clade B).

References

Hoof2010 Ilka Hoof, Carina L. Pérez, Marcus Buggert, Rasmus K. L. Gustafsson, Morten Nielsen, Ole Lund, and Annika C. Karlsson. Interdisciplinary Analysis of HIV-Specific CD8+ T Cell Responses against Variant Epitopes Reveals Restricted TCR Promiscuity. J Immunol, 184(9):5383-5391, 1 May 2010. PubMed ID: 20363973. Show all entries for this paper.


Questions or comments? Contact us at immuno@lanl.gov
 
Managed by Triad National Security, LLC for the U.S. Department of Energy’s National Nuclear Security Administration
Copyright © 2022 Triad National Security, LLC | Disclaimer/Privacy

Dept of Health & Human Services Los Alamos National Institutes of Health